相关实验视频
Updated: Jun 4, 2025

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.5K
多功能NO超分子纳米药物用于降低血栓风险和抑制内脏增生
Kuangshi Zhou1,2,3, Chengchen Huang1,2,3, Jian Li1,2,3,4
1Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China. minshang@zju.edu.cn.
Journal of materials chemistry. B
|January 2, 2025
概括
这项研究开发了一种新型纳米药物,该药物释放氧化 (NO) 和抗氧化剂来治疗血管损伤. 这种创新方法有效地恢复心血管疾病 (CVD) 的血管平衡.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 心血管研究研究心血管研究
背景情况:
- 心血管疾病 (CVD) 是全球主要的死亡原因,发病率和死亡率不断增加.
- 目前对心血管疾病的治疗策略需要加强,以改善患者的治疗结果和寿命.
- 基于氧化 (NO) 的疗法有希望,但在有效的交付和应用方面面临挑战.
研究的目的:
- 开发一种新型的超分子纳米药物,能够同时提供氧化 (NO) 和抗氧化剂.
- 增强与心血管疾病相关的血管损伤的治疗疗效.
- 克服当前NO基治疗心血管疾病的局限性.
主要方法:
- 开发使用α-cyclodextrin (α-CD) 作为宿主分子的超分子纳米医学.
- 纳入向酸以进行特定部位的传递和选择性积累.
- 评估纳米药物清除活性氧物种 (ROS) 和放大NO效应的能力.
主要成果:
- 开发的纳米药物证明了NO和抗氧化剂的有效联合交付.
- 实现了特定地点的输送,导致受伤地点的选择性积累.
- 在急性和慢性心血管疾病模型中,纳米药物成功地清除了ROS,并恢复了血管平衡.
结论:
- 新的超分子纳米医学为心血管疾病提供了一个有前途的治疗策略.
- 这种方法有效地解决了基于NO的疗法所面临的挑战,通过提高输送和疗效.
- 这些发现可能会激励未来研究先进的纳米医学,用于治疗血管损伤和心血管疾病.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
607
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
607
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
465
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
465
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Clot Retraction and Fibrinolysis
3.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.8K

